Compass Q3: $163M Cash Into 2028, Loss Widens to $27.2M as FDA Standoff Persists
CMPX is trading near its 52-week low of $0.671 (13% above the low).
Summary
Compass ended Q3 with $163 million in cash, enough to fund operations into 2028, while its net loss widened to $27.2 million on sharply higher tovecimig manufacturing and pre-commercialization spending. Despite the agency's September request for a new survival trial, the company continues to press the FDA for a BLA path for tovecimig.
Key Events · Earnings and Guidance · CMPX
-
Q3 Loss Widens to $27.2M
Net loss for the quarter ended September 30, 2026 was $27.2 million, or $0.15 per share, versus $14.3 million, or $0.08 per share, a year earlier. Nine-month net loss reached $70.6 million.
-
Cash of $163M Funds Into 2028
Cash and marketable securities totaled $163 million at September 30, 2026, down from $209 million at December 31, 2025, after $48 million used in operating activities. Management expects runway into 2028.
-
Spending Jumps on Tovecimig Prep
R&D rose 72% to $22.0 million, including $8.6 million of tovecimig manufacturing costs, and G&A rose 126% to $6.8 million on $1.8 million more stock-based compensation and $1.5 million of pre-commercialization expense.
-
FDA Survival-Trial Demand Unresolved
Compass says it will further engage the FDA, which in September 2026 recommended an additional survival-benefit study before a BLA submission. The company maintains a new trial is not warranted based on COMPANION-002 data.
Analysis · CMPX · Life Sciences
Cash is the headline this quarter: $163 million at September 30 keeps the company funded into 2028, and that matters because the FDA told Compass in September it wants a new overall-survival trial before any BLA for tovecimig — a demand the company is publicly refusing. That standoff is the real risk to the thesis, and nothing in this release resolves it; Compass says only that it will 'further engage' with the agency. Spending is climbing fast to support that fight: R&D rose 72% to $22.0 million on $8.6 million of tovecimig manufacturing, and G&A more than doubled to $6.8 million on pre-commercialization and stock-comp costs. On the other side, the full COMPANION-002 dataset is now peer-reviewed and published, with a crossover-adjusted OS hazard ratio of 0.85 that the company will lean on in its FDA argument — though that figure was not statistically significant (p=0.53).
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CMPX was trading at $0.76 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $136.7M. The 52-week trading range was $0.67 to $6.88. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.